Actively Recruiting
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
Led by University Health Network, Toronto · Updated on 2026-05-01
20
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).
CONDITIONS
Official Title
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated written informed consent
- Aged 18 years or older
- On peritoneal dialysis with residual kidney function defined as at least 250 cc urine output per day and minimum measured GFR of 2 ml/min/1.73m2 within the last 3 months
- Stable peritoneal dialysis prescription
- Stable dose of RAAS blockers for the last 30 days if applicable
You will not qualify if you...
- Type 1 diabetes
- Acute coronary syndrome or stroke within 30 days before screening
- Peritoneal dialysis peritonitis within 30 days of screening
- History of organ transplant including pancreas, pancreatic islet cells, or kidney
- Planned surgeries or radiologic procedures requiring contrast during the trial
- Pregnant, planning pregnancy, or nursing during the study
- History of diabetic ketoacidosis
- Blood disorders causing hemolysis or unstable red blood cells
- Alcohol or drug abuse within 3 months before screening
- Use of SGLT2 inhibitors within 30 days before screening
- Participation in another investigational drug trial within 30 days before screening
- Unable to understand or comply with study requirements
- Other clinical conditions that might endanger safety or affect study outcomes such as immunocompromised status, active cancer, risk of genital or fungal infections, chronic viral infections, uncontrolled high blood pressure, cardiorenal or hepatorenal syndrome, or severe liver problems
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Toronto General Hospital
Toronto, Ontario, Canada, M5G2N2
Actively Recruiting
Research Team
V
Vesta Lai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here